Mini Review | Volume: 7, Issue: 1, January, 2017
Mini Review | Volume: 7, Issue: 1, January, 2017
Cholinesterase inhibitors are used for the symptomatic treatment of patients with Alzheimer’s disease (AD). This population often has numerous comorbidities and is treated with multiple medications, which leads to polypharmacy. Possible pharmacokinetic and pharmacodynamic drug interactions may occur with this type of concomitant treatment, such as interactions with antipsychotics, antidepressants, anticholinergics, and cardiovascular and urinary disorder medications. Drug interactions should always be considered to reduce the risk of side effects and other problems for patients and also to increase the effectiveness of therapeutic drugs for AD.
Sara Ataei, Maryam Mehrpouya, Amir Nili-Ahmadabadi., Potential drug interactions with cholinesterase inhibitors in Alzheimer patients: A guideline for Neurologists. J App Pharm Sci, 2017; 7 (01): 223-226.
Year
Month
Biological Activities of Plants used in Egyptian Ethnopharmacology
Synergistic antibacterial interaction between Melissa officinalis extracts and antibiotics
Olgica Stefanovic, Ljiljana ComicEvaluation of prescription pattern of psycholeptic medications at hospital discharge for patients with cardiovascular diseases in national cardiovascular disease hospital of Bangladesh